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Circumventing genomic modification in induced pluripotent stem cell (iPSC) derivation is a clear requirement
to realize safe clinical applications. In this issue of Cell Stem Cell, Ichida et al., (2009) describe a small mole-
cule capable of replacing Sox2, offering insight into the reprogramming process.Reactivation of the pluripotency network
in somatic cells through transgenic over-
expressionof adefinedset of transcription
factors—Oct4, Klf4, Sox2, and c-Myc—
leads to the generation of inducedpluripo-
tent stem cells (iPSCs) with embryonic
stem cell (ESC)-like characteristics (Taka-
hashi and Yamanaka, 2006). Although
these cells hold immense promise in real-
izing personalized stem cell therapies,
standard viral vectors result in permanent
genomic modification, obstructing the
safe application of iPSC derivatives. For
therapeutic purposes, acceptable iPSC
production techniques must make use of
alternatives to oncogenes and/or employ
transgenic methods free of permanent
genomic modification (reviewed in O’Mal-
ley et al., 2009).
A major goal in the reprogramming field
is to develop a cocktail consisting of
chemical additives (and recombinant pro-
teins, potentially) that can induce reprog-
ramming of clinically accessible adult
human cells at high efficiency, without
the need for genetic factors (reviewed in
Feng et al., 2009). To this end, a number
of small molecules have been described
that increase the efficiency of reprogram-
ming. For example, histone deacetylase
(HDAC) and methyltransferase (HMTase)
inhibitors induce global changes in chro-
matin structure that are postulated to
assist the reprogramming process by
reducing activation thresholds to achieve
endogenous gene expression patterns.
In particular, valproic acid increases
reprogramming efficiency to the point
that rare iPSC lines can be established in
the absence of c-Myc and Klf4 (Huangfu
et al., 2008). However, to replace Oct4and Sox2, genes occupying central nodes
in the pluripotency transcriptional network,
small molecules that activate the pluripo-
tency network and directly or indirectly
repress other transcriptional programs
are required.
In this issue of Cell Stem Cell, Ichida
et al. (2009) describe the results of
a high-content chemical screen geared
toward the discovery of molecules capa-
ble of reprogramming mouse fibroblasts
in the absence of virally transduced Sox2.
The lead molecule, E-616452 (RepSox, or
Replacer of Sox2), a Transforming Growth
Factor-b Receptor 1 (Tgfbr1/Alk5) kinase
inhibitor, was capable of replacing the
function of Sox2 in MEFs infected with
Oct4, Klf4, and c-Myc only, through
a mechanism that did not involve direct
activation of endogenous Sox2 or Sox2
family member expression. Antibody
depletion of Tgf-b ligands and an anti-
Tgf-bII antibody, as well as a nonspecific
Tgfbr1 inhibitor (SB-431542; Alk-4, -5,
and -7), resulted in similar levels of
enhancement. iPSCs derived in the pres-
ence of RepSox were molecularly and
functionally equivalent to iPSCs that arise
from standard induction methods, con-
tributing to adult chimeras, and the
embryonic germline. Previously, it was
observed that the small molecules BIX
and BayK, HMTase and L-type calcium
channel inhibitors, respectively, may also
be used to replace Sox2 in mouse fibro-
blast reprogramming (Shi et al., 2008).
Thus, the isolation of specialized cell
types already expressing endogenous
reprogramming factors, such as Sox2-
expressing neural progenitor cells, may
not be necessary (Eminli et al., 2008).Cell Stem Cell 5In a similar report, Maherali and Ho-
chedlinger (2009) demonstrated enhanced
efficiency and kinetics of 4-factor reprog-
ramming using the same Tgfbr1 inhibitors
(E-616452/RepSox and SB-431542). This
finding is contrary to Ichida et al. who
observed only a minor impact on overall
efficiency. While both groups utilized the
same compounds, there were significant
differences in their experimental designs,
including the reprogramming induction
strategies, compound concentrations,
kinetics of compound application, and
the assays quantifying reprogramming
efficiency. Reassuringly, their critical find-
ings are consistent despite these differ-
ences in the protocols used. Both groups
report that inhibition of Tgf-b signaling
early in reprogramming alleviated the
need for transgenic c-Myc expression.
Ichida et al. suggest this effect is not
mediated through direct destabilization
of the MEF transcriptional program but,
rather, through activation of L-Myc, which
can replace c-Myc in reprogramming of
mouse fibroblasts (Nakagawa et al.,
2008). Maherali and Hochedlinger also
demonstrated that inhibition of Tgf-b
signaling at early time points (days 1–3)
during mouse fibroblast reprogramming
could effectively substitute for transgenic
Sox2. In contrast, Ichida et al. did not add
Tgf-b inhibitors until at least day 4 of
reprogramming and found that Sox2
replacement by RepSox is a late event
(beginning day 10 to day 11). Time-course
analysis of RepSox treatment indicated
that MEFs infected with Oct4, Klf4, and c-
Myc required only a 24 hr pulse of RepSox
on day 11 to finalize the reprogramming
process, suggesting that RepSox acts by, November 6, 2009 ª2009 Elsevier Inc. 457
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Previewstriggering an endogenous switch in
partially reprogrammed cells. Interest-
ingly, neither group was able to simulta-
neously replace c-Myc and Sox2 using
inhibitors of Tgf-b signaling.
Using MEFs partially reprogrammed
with only Oct4, Klf4, and c-Myc, Ichida
et al. make a case for RepSox-mediated
activation of Nanog through a series of
correlative events. Nanog transcript
levels increased following treatment with
various Tgf-b inhibitors (RepSox, SB-
431542, and anti-Tgf-b antibodies). How-
ever, endogenous Nanog expression is
normally activated during reprogram-
ming. Thus, is the high level of Nanog
induction observed in partially reprog-
rammed MEFs 4 days after RepSox
addition a by-product of stable reprog-
ramming (i.e., the activation of the pluripo-
tency transcriptional network) or a direct
transcriptional activation of Nanog via
inhibition of Tgf-b signaling as suggested
by the authors? To support their hypoth-
esis, the authors compared the ability of
Nanog to substitute for Sox2 in three-
factor (Oct4, Klf4, and c-Myc) reprogram-
ming experiments. While they found
that Nanog and Sox2 are interchangeable
in primary inductions, this result is not
surprising when one considers that OCT4,
NANOG, and SOX2 function in a feed-
forward autoregulatory motif to activate
transcription of each other. Thus, this
observation does not preclude the possi-
bility that, rather than direct activation of
Nanog by RepSox, the pathways medi-
ated by NANOG and RepSox are parallel
and converge elsewhere within the pluri-
potency network.
How might RepSox activate Nanog
and induce the final stages of reprogram-
ming in partially reprogrammed cells?
Receptor-ligand interactions result in the
activation or suppression of signaling
networks that have broad, cell-context-
dependent effects on gene expression.
Ichida et al. (2009) noted that their458 Cell Stem Cell 5, November 6, 2009 ª20partially reprogrammed cells exhibited
high SMAD3 and activated Id1, -2, and
-3 upon exposure to RepSox, all hallmark
Tgf-b signaling responses. They con-
structed a proposed signaling cascade
built upon the Tgf-b-BMP/SMAD pathway
that was gleaned from data generated
from both human and mouse ESCs. While
the critical nodes of the pluripotency tran-
scriptional network are remarkably well
conserved between mouse and humans,
the signal inputs (growth factors and/or
their small molecule replacers) into pluri-
potency networks are incongruent. Thus,
it is not clear at this time whether the
proposed signaling pathway is valid in
the mouse reprogramming system; addi-
tional work will be required to fully eluci-
date the mechanism of RepSox action in
reprogramming mouse fibroblasts to
iPSCs. More importantly, what are the
consequences of inhibition of Tgf-b sig-
naling on human reprogramming? While
Ichida et al. did not report any data
from human experiments, Maherali and
Hochedlinger (2009) commented that
preliminary tests of Tgf-b inhibition had
no effect on human reprogramming. If
the mode of action of E-616452 is to acti-
vate the pluripotency network, then this
finding would be predicted by the demon-
stration that BMP activation in the
absence of Tgf-b/activin signaling pro-
motes hESC differentiation (Xu et al.,
2008). This point brings up a philosophical
question of whether or not it is best to
perform technically facile small molecule
screens in the mouse and then analyze
hits in humans, or directly perform the
screens in humans? What percentage of
the small molecules will maintain similar
effects across species?
Extracting themes from these screens,
on theother hand—such as those temporal
events which impact cell state transitions,
chromatin remodeling, suppression of
differentiation, and maintenance of pluri-
potency—will direct the search for appro-09 Elsevier Inc.priate activators of equivalent pathways in
human cells. The efforts of these and
other groups have demonstrated that
enhancer screens may be performed in
the reprogramming scenario; perhaps
focus should now be placed on trans-
lating these screening methodologies to
a human platform. It may be that we never
completely replace specific factors in the
reprogramming process, as context is
key in pathway activation and cell state
transitions. Combinations of small mole-
cules and protein transduction may even-
tually prove most promising.
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